Peter de Bruijn

Peter de Bruijn is a Researcher in the Department of Medical Oncology at Erasmus University Rotterdam, specializing in cancer pharmacology with a focus on pharmacokinetics, drug-drug interactions, and glioblastoma therapeutics. His work bridges laboratory research and clinical applications to optimize oncology drug efficacy and safety.

His core research domains include:

• Pharmacokinetics & Drug Metabolism: Investigating drug processing mechanisms in cancer patients, particularly involving enzymes like CYP3A4 and transporters such as OATP1B1.
• Drug-Drug Interaction Studies: Analyzing clinically significant interactions (e.g., between semaglutide and alectinib) that impact chemotherapy bioavailability.
• Glioblastoma Innovation: Developing image-guided surgical nanoprobes and repurposing CNS-penetrant drugs to overcome blood-brain barrier limitations.
• Analytical Methodology: Applying quadrupole mass spectrometry for precise drug characterization and transporter substrate screening.

Recent publications (2024-2025) reveal a cohesive trajectory toward personalized cancer therapy, emphasizing transporter-mediated drug uptake, nanoparticle delivery systems, and real-world drug interaction risks. His collaborative approach spans oncology, pharmacology, and analytical chemistry to address critical treatment barriers in malignancies.